FGFR4 mutation	Non Small Cell Lung Cancer	FGFR4 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
FGFR4 mutation	Solid Tumor	FGFR4 mutation	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR4 mutation	Gastric Cancer	FGFR4 mutation	Gastric Cancer	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D

FGFR4 mutation

Associations